Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 12/20 | 0.88 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.64 |
| ▸ | MC3R | P41968 | 1/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.64 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.64 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120982 | 0.98 | ADORA2B (0.85) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL19969384 | 0.98 | ADORA2B (0.85) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL16120999 | 0.98 | ADORA2B (0.85) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL16120983 | 0.98 | ADORA2B (0.85) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL16120989 | 0.98 | ADORA2B (0.85) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL16121000 | 0.98 | ADORA2B (0.85) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL16120979 | 0.97 | ADORA2B (0.85) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL31482443 | 0.95 | ADORA2B (0.81) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL10394216 | 0.94 | ADORA2B (0.78) | ADORA2BRXFP1MAPK1LMNAMAPT | |
| SCHEMBL11701929 | 0.94 | ADORA2B (0.78) | ADORA2BRXFP1MAPK1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634434-B2 | Bifunctional alpha-synuclein binding agents and uses thereof | UNIVERSITY OF SASKATCHEWAN (CA) | 2023-04-25 | — | — | US | disclosed |
| US-20200062782-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2020-02-27 | — | — | US | disclosed |
| WO-2018045464-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2018-03-15 | — | — | WO | disclosed |
| US-20170349317-A1 | GAS BARRIER ENHANCING ADDITIVES AND METHODS | THE COCA-COLA COMPANY | 2017-12-07 | — | — | US | disclosed |
| US-20170349317-A1 | GAS BARRIER ENHANCING ADDITIVES AND METHODS | THE COCA-COLA COMPANY | 2017-12-07 | — | — | US | disclosed |
| US-9764872-B2 | Gas barrier enhancing additives and methods | THE COCA-COLA COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-9764872-B2 | Gas barrier enhancing additives and methods | THE COCA-COLA COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160031583-A1 | GAS BARRIER ENHANCING ADDITIVES AND METHODS | CSPC INNOVATION PHARMACEUTICAL CO., LTD. (CN) | 2016-02-04 | — | — | US | disclosed |
| US-20160031583-A1 | GAS BARRIER ENHANCING ADDITIVES AND METHODS | CSPC INNOVATION PHARMACEUTICAL CO., LTD. (CN) | 2016-02-04 | — | — | US | disclosed |
| WO-2014152788-A1 | GAS BARRIER ENHANCING ADDITIVES AND METHODS | THE COCA-COLA-COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062782-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | SNCA, PARK7, SYNJ2 | ADORA2B 2511/4885RXFP1 3994/4885MAPK1 4308/4885 |
| US-11634434-B2 | Bifunctional alpha-synuclein binding agents and uses thereof | SNCA, PARK7, SYNJ2 | ADORA2B 2511/4885RXFP1 3994/4885MAPK1 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.